Literature DB >> 15618069

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.

Emmanouil S Brilakis1, Joseph P McConnell, Ryan J Lennon, Ahmad A Elesber, Jeffrey G Meyer, Peter B Berger.   

Abstract

AIMS: We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary artery disease (CAD) risk factors, with the severity of angiographic CAD, and with the incidence of major adverse events. METHODS AND
RESULTS: We measured Lp-PLA2 levels in 504 consecutive patients undergoing clinically indicated coronary angiography. Mean age was 60+/-11 years and 38% were women. The mean (+/-SD) Lp-PLA2 level (ng/mL) was 245+/-91. Lp-PLA2 levels correlated with male gender, LDL, HDL, and total cholesterol, fibrinogen, and creatinine. Lp-PLA2 levels correlated with the extent of angiographic CAD on univariate but not on multivariable analysis. During a median follow-up of 4.0 years, 72 major adverse events occurred in 61 of 466 (13%) contacted patients (20 deaths, 14 myocardial infarctions, 28 coronary revascularizations, and 10 strokes). Higher Lp-PLA2 levels were associated with a greater risk of events: the hazard ratio per SD was 1.28 (95% CI 1.06-1.54, P=0.009), and remained significant after adjusting for clinical and lipid variables and C-reactive protein.
CONCLUSION: Higher Lp-PLA2 levels were associated with a higher incidence of major adverse events at follow-up, independently of traditional CAD risk factors and C-reactive protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15618069     DOI: 10.1093/eurheartj/ehi010

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  64 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Cloning, expression, and purification of lipoprotein-associated phospholipase A(2) in Pichia pastoris.

Authors:  Fujun Zhang; Yiping Wang
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

3.  Use of biomarkers to develop treatment strategies for atherosclerosis.

Authors:  Mark A Crandall; Marshall A Corson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

4.  Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Authors:  A Ross Eckard; C T Longenecker; Y Jiang; S M Debanne; D Labbato; N Storer; G A McComsey
Journal:  HIV Med       Date:  2014-03-20       Impact factor: 3.180

Review 5.  Novel markers of inflammation in atherosclerosis.

Authors:  Salim S Virani; Venkateshwar R Polsani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

6.  Circulating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy.

Authors:  Jean Kyung Paik; Minkyung Kim; Minjoo Kim; Yuna Yen; Hyeon Yeong Ahn; Sang-Hyun Lee; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2015

7.  Lipoprotein-associated phospholipase A2 is associated with postpartum hypertension in women with history of preeclampsia.

Authors:  Yuheng Zhou; Jianmin Niu; Dongmei Duan; Qiong Lei; Jiying Wen; Xiaohong Lin; Lijuan Lv; Longding Chen
Journal:  Heart Vessels       Date:  2014-04-23       Impact factor: 2.037

Review 8.  The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Authors:  Salim S Virani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

9.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

10.  Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes.

Authors:  Ida J Hatoum; Frank B Hu; Jeanenne J Nelson; Eric B Rimm
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.